Company environment · Targeted small molecules · FDA CDER & EMA
A targeted cancer pill and its patient test
Original application and later supplements. Start at the top to see what the company does, then the jobs AI models were given here and how each scored.
1What does this company do?
A drug company with a targeted pill for cancers driven by a specific gene change.
Patients qualify only if a test finds the gene change, so the drug’s evidence, its label and the testing strategy must line up.
For experts
Oncology sponsor whose indication depends on a molecular selection test; regulatory, clinical, and companion-diagnostic work share one filing record.
2Where is the product on its way to patients?
Filed for approval, then filed again for new uses in the US and Europe.
- 1Discovery
- 2Lab & animal studies
- 3Human trials
- 4Filing & review
- The product is here
- 5Approved
- 6On the market
Jobs sit at the original filing, a later US supplement, and a European variation.
For experts
Targeted oncology small molecule; snapshots at the original-NDA freeze review, a supplemental filing, a diagnostic-strategy briefing, and an EU Type II variation — four seats, one file.
3What is happening right now?
A filing committee meets tomorrow, and the working files contradict each other.
The team must decide what each dated body of evidence supports and produce a conclusion someone can sign.
4Which jobs were the models given?
5 jobs, each graded against a specialist’s checklist.
Scores are checks passed out of checks in the list. Each model ran each job once.
This company’s files stay private.
The jobs on this page are scored as part of the official 71-task benchmark. The files, the model’s steps, and each check stay unpublished, because they come from a real product’s records. To follow a job all the way down, open one of our open companion showcases (evaluated separately from the benchmark totals).
Havenor Therapeutics (fictional showcase) →
Broad Institute (public FDA record showcase) →